{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:00:50Z","timestamp":1788732050570,"version":"build-2803163510"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06406-0","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T02:46:00Z","timestamp":1776653160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A molecular landscape tracking the progression of non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"44","author":[{"given":"Giuseppe","family":"Cesta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Zolfanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Lauciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Di Giacomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Di Paola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Bravoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geppino","family":"Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-4660","authenticated-orcid":false,"given":"Claudia","family":"Sabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"issue":"3","key":"6406_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"6406_CR2","doi-asserted-by":"crossref","unstructured":"Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pi\u00f1eros M, Znaor A, et al. (2021) Cancer statistics for the year 2020: An overview. Int J Cancer","DOI":"10.1002\/ijc.33588"},{"issue":"6","key":"6406_CR3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.eururo.2020.09.006","volume":"78","author":"J-C Teoh","year":"2020","unstructured":"Teoh J-C, Huang J, Ko W-K, Lok V, Choi P, Ng C-F et al (2020) Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol 78(6):893\u2013906","journal-title":"Eur Urol"},{"issue":"4","key":"6406_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.euf.2023.03.017","volume":"9","author":"CD Gaffney","year":"2023","unstructured":"Gaffney CD, Katims A, D\u2019Souza N, Bjurlin MA, Matulewicz RS (2023) Bladder cancer carcinogens: opportunities for risk reduction. Eur Urol Focus 9(4):575\u2013578","journal-title":"Eur Urol Focus"},{"key":"6406_CR5","unstructured":"https:\/\/monographs.iarc.who.int\/wp-content\/uploads\/2019\/07\/Classifications_by_cancer_site.pdf [Internet]. [cited 2025 Jun 23]. Available from: https:\/\/monographs.iarc.who.int\/wp-content\/uploads\/2019\/07\/Classifications_by_cancer_site.pdf"},{"key":"6406_CR6","doi-asserted-by":"crossref","unstructured":"Alouini S (2025) Risk Factors Associated with Urothelial Bladder Cancer. Int J Environ Res Public Health 21(7).","DOI":"10.3390\/ijerph21070954"},{"key":"6406_CR7","volume":"34","author":"JT Brown","year":"2023","unstructured":"Brown JT, Narayan VM, Joshi SS, Harik L, Jani AB, Bilen MA (2023) Challenges and opportunities in the management of non-urothelial bladder cancers. Cancer Treat Res Commun 34:100663","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"6406_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s42047-020-00066-z","volume":"3","author":"SC Santana","year":"2020","unstructured":"Santana SC, de Souza MF, Amaral MEP, Athanazio DA (2020) Divergent differentiation and variant morphology in invasive urothelial carcinomas \u2013 association with muscle-invasive disease. Surg Exp Pathol 3(1):14","journal-title":"Surg Exp Pathol"},{"issue":"384","key":"6406_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076743","volume":"12","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran A, Cookson MS, Guercio BJ, Cheng L (2024) Advances in diagnosis and treatment of bladder cancer. BMJ 12(384):e076743","journal-title":"BMJ"},{"issue":"1","key":"6406_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL et al (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75\u201394","journal-title":"Eur Urol"},{"issue":"1","key":"6406_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J et al (2023) Bladder cancer. Nat Rev Dis Primers 9(1):58","journal-title":"Nat Rev Dis Primers"},{"key":"6406_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612596","author":"F Claps","year":"2023","unstructured":"Claps F, Pavan N, Ongaro L, Tierno D, Grassi G, Trombetta C et al (2023) BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241612596","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6406_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol 11(3):153\u2013162","journal-title":"Nat Rev Urol"},{"issue":"1","key":"6406_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"AJ Witjes","year":"2024","unstructured":"Witjes AJ, Bruins MH, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA et al (2024) European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 Guidelines. Eur Urol 85(1):17\u201331","journal-title":"Eur Urol"},{"issue":"5","key":"6406_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.kjms.2016.03.002","volume":"32","author":"B Gunlusoy","year":"2016","unstructured":"Gunlusoy B, Ceylan Y, Degirmenci T, Aydogdu O, Bozkurt IH, Yonguc T et al (2016) The potential effect of age on the natural behavior of bladder cancer: does urothelial cell carcinoma progress differently in various age groups? Kaohsiung J Med Sci 32(5):261\u2013266","journal-title":"Kaohsiung J Med Sci"},{"issue":"4","key":"6406_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3233\/BLC-220055","volume":"8","author":"F Guerrero-Ramos","year":"2022","unstructured":"Guerrero-Ramos F, Subiela JD, Rodr\u00edguez-Faba \u00d3, Aumatell J, Manfredi C, Bozzini G et al (2022) Predicting recurrence and progression in patients with non-muscle-invasive bladder cancer: systematic review on the performance of risk stratification models. Bladder Cancer 8(4):339\u2013357","journal-title":"Bladder Cancer"},{"key":"6406_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215297","author":"E Lavallee","year":"2021","unstructured":"Lavallee E, Sfakianos JP, Mulholland DJ (2021) Tumor heterogeneity and consequences for bladder cancer treatment. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13215297","journal-title":"Cancers (Basel)"},{"issue":"6","key":"6406_CR18","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.21037\/tau.2020.03.13","volume":"9","author":"HW Kang","year":"2020","unstructured":"Kang HW, Kim W-J, Choi W, Yun SJ (2020) Tumor heterogeneity in muscle-invasive bladder cancer. Transl Androl Urol 9(6):2866\u20132880","journal-title":"Transl Androl Urol"},{"issue":"9","key":"6406_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00523","volume":"25","author":"X Chen","year":"2019","unstructured":"Chen X, Jiang F, Jia C, Liu M, Nan Y, Qu L et al (2019) Comprehensive gene expression analysis in NMIBC using RNA-seq reveals new therapy strategies. Front Oncol 25(9):523","journal-title":"Front Oncol"},{"issue":"1","key":"6406_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73642-8","volume":"10","author":"C Le Goux","year":"2020","unstructured":"Le Goux C, Vacher S, Schnitzler A, Barry Delongchamps N, Zerbib M, Peyromaure M et al (2020) Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. Sci Rep 10(1):16641","journal-title":"Sci Rep"},{"issue":"18","key":"6406_CR21","doi-asserted-by":"publisher","first-page":"R797","DOI":"10.1016\/j.cub.2004.09.021","volume":"14","author":"S Gadde","year":"2004","unstructured":"Gadde S, Heald R (2004) Mechanisms and molecules of the mitotic spindle. Curr Biol 14(18):R797-805","journal-title":"Curr Biol"},{"issue":"3","key":"6406_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrm.2016.162","volume":"18","author":"SL Prosser","year":"2017","unstructured":"Prosser SL, Pelletier L (2017) Mitotic spindle assembly in animal cells: a fine balancing act. Nat Rev Mol Cell Biol 18(3):187\u2013201","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Pt 7","key":"6406_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1242\/jcs.081406","volume":"124","author":"JC Pease","year":"2011","unstructured":"Pease JC, Tirnauer JS (2011) Mitotic spindle misorientation in cancer\u2013out of alignment and into the fire. J Cell Sci 124(Pt 7):1007\u20131016","journal-title":"J Cell Sci"},{"issue":"5","key":"6406_CR24","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00428-013-1473-6","volume":"463","author":"J-W Choi","year":"2013","unstructured":"Choi J-W, Kim Y, Lee J-H, Kim Y-S (2013) High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch 463(5):681\u2013687","journal-title":"Virchows Arch"},{"issue":"9\u201310","key":"6406_CR25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1101\/gad.314351.118","volume":"32","author":"MS Levine","year":"2018","unstructured":"Levine MS, Holland AJ (2018) The impact of mitotic errors on cell proliferation and tumorigenesis. Genes Dev 32(9\u201310):620\u2013638","journal-title":"Genes Dev"},{"issue":"1","key":"6406_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89628-z","volume":"11","author":"D-C Yu","year":"2021","unstructured":"Yu D-C, Chen X-Y, Li X, Zhou H-Y, Yu D-Q, Yu X-L et al (2021) Transcript levels of spindle and kinetochore-associated complex 1\/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma. Sci Rep 11(1):11165","journal-title":"Sci Rep"},{"issue":"12","key":"6406_CR27","doi-asserted-by":"publisher","first-page":"10131","DOI":"10.1007\/s00432-023-04906-9","volume":"149","author":"R Shen","year":"2023","unstructured":"Shen R, Li Z, Wu X (2023) The mitotic spindle-related seven-gene predicts the prognosis and immune microenvironment of lung adenocarcinoma. J Cancer Res Clin Oncol 149(12):10131\u201310141","journal-title":"J Cancer Res Clin Oncol"},{"key":"6406_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312756","author":"X-M Piao","year":"2021","unstructured":"Piao X-M, You C, Byun YJ, Kang HW, Noh J, Lee J et al (2021) Prognostic value of BUB1 for predicting non-muscle-invasive bladder cancer progression. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222312756","journal-title":"Int J Mol Sci"},{"issue":"3","key":"6406_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3233\/CBM-181202","volume":"22","author":"S Jiang","year":"2018","unstructured":"Jiang S, Tian F, Wang Q, Cheng W, Wang L, Wang Y et al (2018) High expression of spindle and kinetochore- associated protein 1 predicts early recurrence and progression of non-muscle invasive bladder cancer. Cancer Biomark 22(3):543\u2013549","journal-title":"Cancer Biomark"},{"key":"6406_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184673","author":"C You","year":"2021","unstructured":"You C, Piao X-M, Kang K, Kim Y-J, Kang K (2021) Integrative transcriptome profiling reveals SKA3 as a novel prognostic marker in non-muscle invasive bladder cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13184673","journal-title":"Cancers (Basel)"},{"issue":"6","key":"6406_CR31","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1007\/s13277-013-1000-z","volume":"34","author":"L Yan","year":"2013","unstructured":"Yan L, Li S, Xu C, Zhao X, Hao B, Li H et al (2013) Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma. Tumour Biol 34(6):4089\u20134100","journal-title":"Tumour Biol"},{"issue":"2","key":"6406_CR32","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/jcb.26340","volume":"119","author":"L Yan","year":"2018","unstructured":"Yan L, Li Q, Yang J, Qiao B (2018) TPX2-p53-GLIPR1 regulatory circuitry in cell proliferation, invasion, and tumor growth of bladder cancer. J Cell Biochem 119(2):1791\u20131803","journal-title":"J Cell Biochem"},{"issue":"7","key":"6406_CR33","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1158\/1078-0432.CCR-12-2383","volume":"19","author":"N Zhou","year":"2013","unstructured":"Zhou N, Singh K, Mir MC, Parker Y, Lindner D, Dreicer R et al (2013) The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res 19(7):1717\u20131728","journal-title":"Clin Cancer Res"},{"issue":"2","key":"6406_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrm1835","volume":"7","author":"JP Thiery","year":"2006","unstructured":"Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131\u2013142","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"6406_CR35","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420\u20131428","journal-title":"J Clin Invest"},{"issue":"6","key":"6406_CR36","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M et al (2020) Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 21(6):341\u2013352","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"6406_CR37","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1073\/pnas.1120605109","volume":"109","author":"J-P Volkmer","year":"2012","unstructured":"Volkmer J-P, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV et al (2012) Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci USA 109(6):2078\u20132083","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"6406_CR38","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrurol.2012.142","volume":"9","author":"PL Ho","year":"2012","unstructured":"Ho PL, Kurtova A, Chan KS (2012) Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol 9(10):583\u2013594","journal-title":"Nat Rev Urol"},{"issue":"4","key":"6406_CR39","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/stem.1625","volume":"32","author":"GM Dancik","year":"2014","unstructured":"Dancik GM, Owens CR, Iczkowski KA, Theodorescu D (2014) A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells 32(4):974\u2013982","journal-title":"Stem Cells"},{"issue":"10","key":"6406_CR40","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/sj.bjc.6602813","volume":"93","author":"M Aaboe","year":"2005","unstructured":"Aaboe M, Marcussen N, Jensen KME, Thykjaer T, Dyrskj\u00f8t L, Orntoft TF (2005) Gene expression profiling of noninvasive primary urothelial tumours using microarrays. Br J Cancer 93(10):1182\u20131190","journal-title":"Br J Cancer"},{"issue":"6","key":"6406_CR41","doi-asserted-by":"publisher","first-page":"F1477","DOI":"10.1152\/ajprenal.00327.2009","volume":"297","author":"P Khandelwal","year":"2009","unstructured":"Khandelwal P, Abraham SN, Apodaca G (2009) Cell biology and physiology of the uroepithelium. Am J Physiol Renal Physiol 297(6):F1477\u2013F1501","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"6406_CR42","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/labinvest.2017.17","volume":"97","author":"T Migita","year":"2017","unstructured":"Migita T, Ueda A, Ohishi T, Hatano M, Seimiya H, Horiguchi S-I et al (2017) Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. Lab Invest 97(5):567\u2013576","journal-title":"Lab Invest"},{"issue":"1661","key":"6406_CR43","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2014.0042","volume":"370","author":"RT Bryan","year":"2015","unstructured":"Bryan RT (2015) Cell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomena. Philos Trans R Soc Lond B Biol Sci 370(1661):20140042","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"6406_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1083\/jcb.113.1.173","volume":"113","author":"UH Frixen","year":"1991","unstructured":"Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A et al (1991) E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113(1):173\u2013185","journal-title":"J Cell Biol"},{"issue":"2","key":"6406_CR45","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2010.04.016","volume":"184","author":"RT Bryan","year":"2010","unstructured":"Bryan RT, Tselepis C (2010) Cadherin switching and bladder cancer. J Urol 184(2):423\u2013431","journal-title":"J Urol"},{"issue":"1","key":"6406_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/ijbs.77181","volume":"19","author":"S Monteiro-Reis","year":"2023","unstructured":"Monteiro-Reis S, Miranda-Gon\u00e7alves V, Guimar\u00e3es-Teixeira C, Martins-Lima C, Lobo J, Montezuma D et al (2023) Vimentin epigenetic deregulation in Bladder Cancer associates with acquisition of invasive and metastatic phenotype through epithelial-to-mesenchymal transition. Int J Biol Sci 19(1):1\u201312","journal-title":"Int J Biol Sci"},{"issue":"1","key":"6406_CR47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12967-020-02475-w","volume":"18","author":"J Lobo","year":"2020","unstructured":"Lobo J, Monteiro-Reis S, Guimar\u00e3es-Teixeira C, Lopes P, Carneiro I, Jer\u00f3nimo C et al (2020) Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression. J Transl Med 18(1):303","journal-title":"J Transl Med"},{"issue":"19","key":"6406_CR48","doi-asserted-by":"publisher","first-page":"28384","DOI":"10.18632\/oncotarget.8635","volume":"7","author":"Y-L Lin","year":"2016","unstructured":"Lin Y-L, Wang Y-L, Fu X-L, Li W-P, Wang Y-H, Ma J-G (2016) Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer. Oncotarget 7(19):28384\u201328392","journal-title":"Oncotarget"},{"issue":"1","key":"6406_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12307-017-0199-4","volume":"11","author":"R Singh","year":"2018","unstructured":"Singh R, Mandhani A, Agrawal V, Garg M (2018) Positive correlation between matrix metalloproteinases and epithelial-to-mesenchymal transition and its association with clinical outcome in bladder cancer patients. Cancer Microenviron 11(1):23\u201339","journal-title":"Cancer Microenviron"},{"issue":"2","key":"6406_CR50","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1016\/j.clgc.2016.07.021","volume":"15","author":"R Singh","year":"2017","unstructured":"Singh R, Ansari JA, Maurya N, Mandhani A, Agrawal V, Garg M (2017) Epithelial-to-mesenchymal transition and its correlation with clinicopathologic features in patients with urothelial carcinoma of the bladder. Clin Genitourin Cancer 15(2):e187\u2013e197","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"6406_CR51","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.urolonc.2012.02.001","volume":"31","author":"K Wu","year":"2013","unstructured":"Wu K, Zeng J, Zhou J, Fan J, Chen Y, Wang Z et al (2013) Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development. Urol Oncol 31(8):1751\u20131760","journal-title":"Urol Oncol"},{"issue":"4","key":"6406_CR52","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/jjco\/hyz186","volume":"50","author":"M-K Chen","year":"2020","unstructured":"Chen M-K, Chen Z-J, Xiao K-H, Qin Z-K, Ye Y-L, Wen W-J et al (2020) Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer. Jpn J Clin Oncol 50(4):456\u2013464","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"6406_CR53","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/jcmm.14767","volume":"24","author":"R Cao","year":"2020","unstructured":"Cao R, Yuan L, Ma B, Wang G, Qiu W, Tian Y (2020) An EMT-related gene signature for the prognosis of human bladder cancer. J Cell Mol Med 24(1):605\u2013617","journal-title":"J Cell Mol Med"},{"issue":"6","key":"6406_CR54","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41419-019-1669-z","volume":"10","author":"J Huang","year":"2019","unstructured":"Huang J, Lo U-G, Wu S, Wang B, Pong R-C, Lai C-H et al (2019) The roles and mechanism of IFIT5 in bladder cancer epithelial-mesenchymal transition and progression. Cell Death Dis 10(6):437","journal-title":"Cell Death Dis"},{"issue":"3","key":"6406_CR55","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s13577-024-01053-2","volume":"37","author":"M Zarzycka","year":"2024","unstructured":"Zarzycka M, Kotula-Balak M, Gil D (2024) The mechanism of the contribution of ICAM-1 to epithelial-mesenchymal transition (EMT) in bladder cancer. Hum Cell 37(3):801\u2013816","journal-title":"Hum Cell"},{"issue":"9","key":"6406_CR56","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1111\/cas.14126","volume":"110","author":"K-H Xiao","year":"2019","unstructured":"Xiao K-H, Teng K, Ye Y-L, Tan L, Chen M-K, Liang H-T et al (2019) Kinesin family member C1 accelerates bladder cancer cell proliferation and induces epithelial-mesenchymal transition via Akt\/GSK3\u03b2 signaling. Cancer Sci 110(9):2822\u20132833","journal-title":"Cancer Sci"},{"issue":"2","key":"6406_CR57","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.urolonc.2010.01.005","volume":"30","author":"M Muramaki","year":"2012","unstructured":"Muramaki M, Miyake H, Terakawa T, Kumano M, Sakai I, Fujisawa M (2012) Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol 30(2):161\u2013166","journal-title":"Urol Oncol"},{"issue":"3","key":"6406_CR58","doi-asserted-by":"publisher","first-page":"110.e11","DOI":"10.1016\/j.urolonc.2014.08.012","volume":"33","author":"B Liu","year":"2015","unstructured":"Liu B, Miyake H, Nishikawa M, Fujisawa M (2015) Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection. Urol Oncol 33(3):110.e11\u20138","journal-title":"Urol Oncol"},{"issue":"Pt 24","key":"6406_CR59","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1242\/jcs.023820","volume":"123","author":"C Frantz","year":"2010","unstructured":"Frantz C, Stewart KM, Weaver VM (2010) The extracellular matrix at a glance. J Cell Sci 123(Pt 24):4195\u20134200","journal-title":"J Cell Sci"},{"issue":"9","key":"6406_CR60","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","volume":"19","author":"Y-C Lee","year":"2022","unstructured":"Lee Y-C, Lam H-M, Rosser C, Theodorescu D, Parks WC, Chan KS (2022) The dynamic roles of the bladder tumour microenvironment. Nat Rev Urol 19(9):515\u2013533","journal-title":"Nat Rev Urol"},{"issue":"1","key":"6406_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z (2020) Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun 11(1):5120","journal-title":"Nat Commun"},{"issue":"11","key":"6406_CR62","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/35099066","volume":"2","author":"B Geiger","year":"2001","unstructured":"Geiger B, Bershadsky A, Pankov R, Yamada KM (2001) Transmembrane crosstalk between the extracellular matrix-cytoskeleton crosstalk. Nat Rev Mol Cell Biol 2(11):793\u2013805","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"6406_CR63","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19(11):1423\u20131437","journal-title":"Nat Med"},{"key":"6406_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.mbplus.2024.100154","volume":"23","author":"C Venegoni","year":"2024","unstructured":"Venegoni C, Pederzoli F, Locatelli I, Alchera E, Martinez-Vidal L, Di Coste A et al (2024) Topographic modification of the extracellular matrix precedes the onset of bladder cancer. Matrix Biol Plus 23:100154","journal-title":"Matrix Biol Plus"},{"issue":"50","key":"6406_CR65","doi-asserted-by":"publisher","first-page":"82609","DOI":"10.18632\/oncotarget.12089","volume":"7","author":"M Brooks","year":"2016","unstructured":"Brooks M, Mo Q, Krasnow R, Ho PL, Lee Y-C, Xiao J et al (2016) Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget 7(50):82609\u201382619","journal-title":"Oncotarget"},{"issue":"12","key":"6406_CR66","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.2147\/OTT.S194568","volume":"7","author":"H Zhu","year":"2019","unstructured":"Zhu H, Chen H, Wang J, Zhou L, Liu S (2019) Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer. Onco Targets Ther 7(12):3441\u20133457","journal-title":"Onco Targets Ther"},{"issue":"1","key":"6406_CR67","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4111\/icu.20230227","volume":"65","author":"K Kim","year":"2024","unstructured":"Kim K, Byun YJ, Zheng C-M, Moon S, Jo SJ, Kang HW et al (2024) COL6A1 expression as a potential prognostic biomarker for risk stratification of T1 high grade bladder cancer: Unveiling the aggressive nature of a distinct non-muscle invasive subtype. Investig Clin Urol 65(1):94\u2013103","journal-title":"Investig Clin Urol"},{"issue":"10","key":"6406_CR68","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2174\/1566524021666210225100041","volume":"22","author":"M Ingenwerth","year":"2022","unstructured":"Ingenwerth M, Nyir\u00e1dy P, Hadaschik B, Szarvas T, Reis H (2022) The prognostic value of cytokeratin and extracellular collagen expression in urinary bladder cancer. Curr Mol Med 22(10):941\u2013949","journal-title":"Curr Mol Med"},{"issue":"13","key":"6406_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.833989","volume":"3","author":"X Sun","year":"2022","unstructured":"Sun X, Xu H, Liu G, Chen J, Xu J, Li M et al (2022) A robust immuno-prognostic model of non-muscle-invasive bladder cancer indicates dynamic interaction in tumor immune microenvironment contributes to cancer progression. Front Genet 3(13):833989","journal-title":"Front Genet"},{"issue":"9","key":"6406_CR70","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/ijc.32737","volume":"146","author":"G Sj\u00f6dahl","year":"2020","unstructured":"Sj\u00f6dahl G, Eriksson P, Patschan O, Marzouka N-A-D, Jakobsson L, Bernardo C et al (2020) Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma. Int J Cancer 146(9):2636\u20132647","journal-title":"Int J Cancer"},{"issue":"4","key":"6406_CR71","doi-asserted-by":"publisher","first-page":"183","DOI":"10.62347\/XNTC7030","volume":"12","author":"K Cao","year":"2024","unstructured":"Cao K, Shi H, Wu B, Lv Z, Yang R (2024) Identification of ECM and EMT relevant genes involved in the progression of bladder cancer through bioinformatics analysis. Am J Clin Exp Urol 12(4):183\u2013193","journal-title":"Am J Clin Exp Urol"},{"issue":"10","key":"6406_CR72","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/jnci\/djac140","volume":"114","author":"S You","year":"2022","unstructured":"You S, Kim M, Hoi XP, Lee YC, Wang L, Spetzler D et al (2022) Discoidin domain receptor-driven gene signatures as markers of patient response to anti-PD-L1 immune checkpoint therapy. J Natl Cancer Inst 114(10):1380\u20131391","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"6406_CR73","first-page":"2500","volume":"9","author":"X Xie","year":"2017","unstructured":"Xie X, Rui W, He W, Shao Y, Sun F, Zhou W et al (2017) Discoidin domain receptor 1 activity drives an aggressive phenotype in bladder cancer. Am J Transl Res 9(5):2500\u20132507","journal-title":"Am J Transl Res"},{"issue":"48","key":"6406_CR74","doi-asserted-by":"publisher","first-page":"78918","DOI":"10.18632\/oncotarget.12912","volume":"7","author":"M-C Tsai","year":"2016","unstructured":"Tsai M-C, Li W-M, Huang C-N, Ke H-L, Li C-C, Yeh H-C et al (2016) DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study. Oncotarget 7(48):78918\u201378931","journal-title":"Oncotarget"},{"key":"6406_CR75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.humpath.2019.07.002","volume":"91","author":"J Calvete","year":"2019","unstructured":"Calvete J, Larrinaga G, Errarte P, Mart\u00edn AM, Dotor A, Esquinas C et al (2019) The coexpression of Fibroblast Activation Protein (FAP) and basal-type markers (CK 5\/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Hum Pathol 91:61\u201368","journal-title":"Hum Pathol"},{"issue":"1","key":"6406_CR76","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41598-019-55013-0","volume":"10","author":"A Mezheyeuski","year":"2020","unstructured":"Mezheyeuski A, Segersten U, Leiss LW, Malmstr\u00f6m P-U, Hatina J, \u00d6stman A et al (2020) Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome. Sci Rep 10(1):281","journal-title":"Sci Rep"},{"issue":"9","key":"6406_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257195","volume":"16","author":"T Muilwijk","year":"2021","unstructured":"Muilwijk T, Akand M, Daelemans S, Marien K, Waumans Y, Kockx M et al (2021) Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer. PLoS ONE 16(9):e0257195","journal-title":"PLoS ONE"},{"key":"6406_CR78","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.euros.2024.06.011","volume":"66","author":"T Muilwijk","year":"2024","unstructured":"Muilwijk T, Baekelandt L, Akand M, Daelemans S, Marien K, Waumans Y et al (2024) Fibroblast Activation Protein-\u03b1 and the immune landscape: unraveling T1 non-muscle-invasive bladder cancer progression. Eur Urol Open Sci 66:67\u201374","journal-title":"Eur Urol Open Sci"},{"issue":"22","key":"6406_CR79","first-page":"5365","volume":"53","author":"B Davies","year":"1993","unstructured":"Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T et al (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53(22):5365\u20135369","journal-title":"Cancer Res"},{"issue":"1","key":"6406_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X et al (2023) Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer 22(1):48","journal-title":"Mol Cancer"},{"issue":"13","key":"6406_CR81","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1111\/jcmm.16463","volume":"25","author":"K-Y Chou","year":"2021","unstructured":"Chou K-Y, Chang A-C, Ho C-Y, Tsai T-F, Chen H-E, Chen P-C et al (2021) Thrombospondin-4 promotes bladder cancer cell migration and invasion via MMP2 production. J Cell Mol Med 25(13):6046\u20136055","journal-title":"J Cell Mol Med"},{"issue":"1","key":"6406_CR82","first-page":"476","volume":"19","author":"X-M Piao","year":"2020","unstructured":"Piao X-M, Jeong P, Yan C, Kim Y-H, Byun YJ, Xu Y et al (2020) A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncol Lett 19(1):476\u2013486","journal-title":"Oncol Lett"},{"issue":"37","key":"6406_CR83","doi-asserted-by":"publisher","first-page":"40370","DOI":"10.18632\/oncotarget.5458","volume":"6","author":"M-S Lee","year":"2015","unstructured":"Lee M-S, Lee J, Kim JH, Kim WT, Kim W-J, Ahn H et al (2015) Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer. Oncotarget 6(37):40370\u201340384","journal-title":"Oncotarget"},{"issue":"2","key":"6406_CR84","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013847","volume":"98","author":"Y Liu","year":"2019","unstructured":"Liu Y, Wu X, Wang G, Hu S, Zhang Y, Zhao S (2019) CALD1, CNN1, and TAGLN identified as potential prognostic molecular markers of bladder cancer by bioinformatics analysis. Medicine (Baltimore) 98(2):e13847","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"6406_CR85","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12935-021-01896-x","volume":"21","author":"Y Du","year":"2021","unstructured":"Du Y, Jiang X, Wang B, Cao J, Wang Y, Yu J et al (2021) The cancer-associated fibroblasts related gene CALD1 is a prognostic biomarker and correlated with immune infiltration in bladder cancer. Cancer Cell Int 21(1):283","journal-title":"Cancer Cell Int"},{"issue":"14","key":"6406_CR86","first-page":"3512","volume":"59","author":"ZT Zhang","year":"1999","unstructured":"Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR (1999) Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 59(14):3512\u20133517","journal-title":"Cancer Res"},{"issue":"9","key":"6406_CR87","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00432-018-2694-5","volume":"144","author":"S Rinaldetti","year":"2018","unstructured":"Rinaldetti S, Wirtz R, Worst TS, Hartmann A, Breyer J, Dyrskjot L et al (2018) FOXM1 predicts disease progression in non-muscle invasive bladder cancer. J Cancer Res Clin Oncol 144(9):1701\u20131709","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"6406_CR88","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12964-020-00625-7","volume":"18","author":"AS Zangouei","year":"2020","unstructured":"Zangouei AS, Barjasteh AH, Rahimi HR, Mojarrad M, Moghbeli M (2020) Role of tyrosine kinases in bladder cancer progression: an overview. Cell Commun Signal 18(1):127","journal-title":"Cell Commun Signal"},{"issue":"2","key":"6406_CR89","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41585-024-00914-7","volume":"22","author":"M Olislagers","year":"2025","unstructured":"Olislagers M, de Jong FC, Rutten VC, Boormans JL, Mahmoudi T, Zuiverloon TCM (2025) Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification. Nat Rev Urol 22(2):75\u201391","journal-title":"Nat Rev Urol"},{"issue":"12","key":"6406_CR90","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00345-015-1557-9","volume":"33","author":"W Ding","year":"2015","unstructured":"Ding W, Tong S, Gou Y, Sun C, Wang H, Chen Z et al (2015) Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol 33(12):1951\u20131957","journal-title":"World J Urol"},{"issue":"4","key":"6406_CR91","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/2090598X.2020.1814183","volume":"18","author":"V Agrawal","year":"2020","unstructured":"Agrawal V, Bharti N, Pandey R (2020) Human epidermal growth factor receptor 2 (HER2) gene amplification in non-muscle invasive urothelial bladder cancers: identification of patients for targeted therapy. Arab J Urol 18(4):267\u2013272","journal-title":"Arab J Urol"},{"issue":"8","key":"6406_CR92","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3346\/jkms.2015.30.8.1068","volume":"30","author":"SD Lim","year":"2015","unstructured":"Lim SD, Cho YM, Choi G-S, Park HK, Paick SH, Kim WY et al (2015) Clinical significance of substaging and HER2 expression in papillary nonmuscle invasive urothelial cancers of the urinary bladder. J Korean Med Sci 30(8):1068\u20131077","journal-title":"J Korean Med Sci"},{"issue":"15","key":"6406_CR93","doi-asserted-by":"publisher","first-page":"25433","DOI":"10.18632\/oncotarget.15989","volume":"8","author":"L Cormio","year":"2017","unstructured":"Cormio L, Sanguedolce F, Cormio A, Massenio P, Pedicillo MC, Cagiano S et al (2017) Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer. Oncotarget 8(15):25433\u201325441","journal-title":"Oncotarget"},{"issue":"3","key":"6406_CR94","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000453670","volume":"98","author":"J Breyer","year":"2017","unstructured":"Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P et al (2017) ERBB2 expression as potential risk-stratification for early cystectomy in patients with pT1 bladder cancer and concomitant carcinoma in situ. Urol Int 98(3):282\u2013289","journal-title":"Urol Int"},{"key":"6406_CR95","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.anndiagpath.2019.01.002","volume":"39","author":"AE Abdelrahman","year":"2019","unstructured":"Abdelrahman AE, Rashed HE, Elkady E, Elsebai EA, El-Azony A, Matar I (2019) Fatty acid synthase, Her2\/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer. Ann Diagn Pathol 39:42\u201352","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"6406_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0796-y","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C et al (2018) Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer 17(1):45","journal-title":"Mol Cancer"},{"issue":"11","key":"6406_CR97","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2407-11-139","volume":"16","author":"C-Y Yeh","year":"2011","unstructured":"Yeh C-Y, Shin S-M, Yeh H-H, Wu T-J, Shin J-W, Chang T-Y et al (2011) Transcriptional activation of the Axl and PDGFR-\u03b1 by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer 16(11):139","journal-title":"BMC Cancer"},{"issue":"7","key":"6406_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134552","volume":"10","author":"Y-W Kim","year":"2015","unstructured":"Kim Y-W, Yun SJ, Jeong P, Kim S-K, Kim S-Y, Yan C et al (2015) The c-MET network as novel prognostic marker for predicting bladder cancer patients with an increased risk of developing aggressive disease. PLoS ONE 10(7):e0134552","journal-title":"PLoS ONE"},{"key":"6406_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113508","author":"F Song","year":"2022","unstructured":"Song F, Kotolloshi R, Gajda M, H\u00f6lzer M, Grimm M-O, Steinbach D (2022) Reduced IQGAP2 promotes bladder cancer through regulation of MAPK\/ERK pathway and cytokines. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232113508","journal-title":"Int J Mol Sci"},{"issue":"2","key":"6406_CR100","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3892\/ol.2017.6408","volume":"14","author":"HW Kang","year":"2017","unstructured":"Kang HW, Seo SP, Jeong P, Ha Y-S, Kim WT, Kim Y-J et al (2017) Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. Oncol Lett 14(2):2468\u20132474","journal-title":"Oncol Lett"},{"issue":"8","key":"6406_CR101","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/bjc.2012.412","volume":"107","author":"L Dyrskj\u00f8t","year":"2012","unstructured":"Dyrskj\u00f8t L, Reinert T, Novoradovsky A, Zuiverloon TCM, Beukers W, Zwarthoff E et al (2012) Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. Br J Cancer 107(8):1392\u20131398","journal-title":"Br J Cancer"},{"issue":"3","key":"6406_CR102","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.eururo.2017.05.040","volume":"72","author":"L Dyrskj\u00f8t","year":"2017","unstructured":"Dyrskj\u00f8t L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG et al (2017) Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: a prospective multicentre validation study. Eur Urol 72(3):461\u2013469","journal-title":"Eur Urol"},{"issue":"9","key":"6406_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-3","volume":"8","author":"W-J Kim","year":"2010","unstructured":"Kim W-J, Kim E-J, Kim S-K, Kim Y-J, Ha Y-S, Jeong P et al (2010) Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 8(9):3","journal-title":"Mol Cancer"},{"issue":"2","key":"6406_CR104","first-page":"379","volume":"43","author":"H Yin","year":"2020","unstructured":"Yin H, Zhang C, Gou X, He W, Gan D (2020) Identification of a 13\u2011mRNA signature for predicting disease progression and prognosis in patients with bladder cancer. Oncol Rep 43(2):379\u2013394","journal-title":"Oncol Rep"},{"key":"6406_CR105","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejca.2016.06.003","volume":"64","author":"AG van der Heijden","year":"2016","unstructured":"van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fern\u00e1ndez PL et al (2016) A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer 64:127\u2013136","journal-title":"Eur J Cancer"},{"issue":"10","key":"6406_CR106","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2407-10-21","volume":"25","author":"S-K Kim","year":"2010","unstructured":"Kim S-K, Kim E-J, Leem S-H, Ha Y-S, Kim Y-J, Kim W-J (2010) Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancer. BMC Cancer 25(10):21","journal-title":"BMC Cancer"},{"issue":"2","key":"6406_CR107","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/pmic.200500033","volume":"6","author":"JP Tolson","year":"2006","unstructured":"Tolson JP, Flad T, Gnau V, Dihazi H, Hennenlotter J, Beck A et al (2006) Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 6(2):697\u2013708","journal-title":"Proteomics"},{"issue":"14","key":"6406_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1187286","volume":"24","author":"W Wang","year":"2023","unstructured":"Wang W, Zhang X, Jiang S, Xu P, Chen K, Li K et al (2023) A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer. Front Immunol 24(14):1187286","journal-title":"Front Immunol"},{"issue":"3","key":"6406_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102313","volume":"23","author":"GS Kulkarni","year":"2025","unstructured":"Kulkarni GS, Guzzo T, Abbosh PH, Huang WC, Shore N, Smith Z et al (2025) Real-world treatment patterns and outcomes in patients with Bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: a multicountry medical chart review. Clin Genitourin Cancer 23(3):102313","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"6406_CR110","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G et al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Gu\u00e9rin. Eur Urol 69(1):60\u201369","journal-title":"Eur Urol"},{"issue":"5","key":"6406_CR111","doi-asserted-by":"publisher","first-page":"197.e1","DOI":"10.1016\/j.urolonc.2021.12.009","volume":"40","author":"X-M Piao","year":"2022","unstructured":"Piao X-M, Kim YU, Byun YJ, Zheng C-M, Moon SM, Kim K et al (2022) Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. Urol Oncol 40(5):197.e1-197.e9","journal-title":"Urol Oncol"},{"key":"6406_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104092","volume":"81","author":"S-W Baek","year":"2022","unstructured":"Baek S-W, Mun J-Y, Jang I-H, Yang G-E, Jeong M-S, Kim S-K et al (2022) YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer. EBioMedicine 81:104092","journal-title":"EBioMedicine"},{"issue":"1","key":"6406_CR113","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bju.14525","volume":"123","author":"J Breyer","year":"2019","unstructured":"Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R et al (2019) FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. BJU Int 123(1):187\u2013196","journal-title":"BJU Int"},{"issue":"4","key":"6406_CR114","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","volume":"78","author":"AG Robertson","year":"2020","unstructured":"Robertson AG, Groeneveld CS, Jordan B, Lin X, McLaughlin KA, Das A et al (2020) Identification of differential tumor subtypes of T1 bladder cancer. Eur Urol 78(4):533\u2013537","journal-title":"Eur Urol"},{"key":"6406_CR115","doi-asserted-by":"crossref","unstructured":"de Jong FC, Laajala TD, Hoedemaeker RF, Jordan KR, van der Made ACJ, Boev\u00e9 ER, et al. (2023) Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin. Sci Transl Med 15(697): eabn4118","DOI":"10.1126\/scitranslmed.abn4118"},{"issue":"9","key":"6406_CR116","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/1541-7786.MCR-15-0120","volume":"13","author":"C Cheng","year":"2015","unstructured":"Cheng C, Varn FS, Marsit CJ (2015) E2F4 program is predictive of progression and intravesical immunotherapy efficacy in bladder cancer. Mol Cancer Res 13(9):1316\u20131324","journal-title":"Mol Cancer Res"},{"key":"6406_CR117","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3): 466\u20135; discussion 475.","DOI":"10.1016\/j.eururo.2005.12.031"},{"issue":"3","key":"6406_CR118","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447\u2013461","journal-title":"Eur Urol"},{"key":"6406_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215500","author":"A Lopez-Beltran","year":"2021","unstructured":"Lopez-Beltran A, Blanca A, Cimadamore A, Gogna R, Montironi R, Cheng L (2021) Molecular classification of bladder urothelial carcinoma using nanostring-based gene expression analysis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13215500","journal-title":"Cancers (Basel)"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06406-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:02:08Z","timestamp":1779876128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06406-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6406"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06406-0","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}],"article-number":"320"}}